Autopsy report · NCT05625087

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 11 months before it started.
Ran for about 2 years 3 months before it stopped.
4 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: UNICANCER
Sponsor type: University, hospital or other
Conditions: Breast Cancer Stage IV
Interventions: Alpelisib; Ribociclib
Participants: 4
Sites: 44
Countries: France

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.